Singapore, Aug. 31 -- CanSino Biologics reported continued momentum in its international business during the first half of 2026, alongside progress across its marketed vaccines, regulatory-stage products and next-generation pipeline.

The company recorded approximately RMB550 million in revenue for the period, an increase of 43.8% year-on-year, while its net loss attributable to shareholders narrowed significantly.

Overseas revenue reached RMB150 million as CanSinoBIO continued to expand mature products into international markets and develop broader partnership models involving technology collaboration and local industrialisation.

The company said its overseas business is increasingly evolving beyond finished-product exports towards a m...